BioCad and Shanghai Pharmaceutical Holding entered into a Memorandum of Understanding to create two joint ventures for production, clinical development, registration, and marketing of several high-cost medicines based on monoclonal antibodies in the People’s Republic of China.
September 12, 2018
· 2 min read
